Key appointment as Barton moves toward development and operations

HIGHLIGHTS

• Appointment of Ms Sylvia Rapo as Barton’s new Head of Corporate Affairs and Sustainability

• ~25 years’ South Australian experience in corporate affairs, communications, government relations, media management and sustainability, including with JBS&G, BAE Systems Australia, ElectraNet, Beach Energy, and the Office of the Premier and Department for Environment & Natural Resources

Matthew C. Zorn previously argued that federal regulators determine “accepted medical use” through the FDA approval framework. Today, he appears on behalf of the United States defending a CMS program that introduces cannabinoid furnishing into Medicare connected clinical environments without FDA validation. The contradiction raises serious policy questions: if FDA approval defines medical legitimacy under federal law, how can Medicare linked access pathways expand before that standard is met? Programs like BEI risk signaling that clinical evidence is optional – a message that directly undermines companies investing years in FDA authorized cannabinoid drug development.